PTEN and cancer: In particular, the loss of PTEN has garnered increased clinical significance due to its prevalence in many cancer subtypes, its contribution toward an immunosuppressive TIME, and its recent appreciation for being a prognostic marker for patient response toward immune checkpoint inhibition (61).